Evidence map›Paper›PMID 38952672›Full record

ArticleOncoimmunology2024

Complete response of metastatic microsatellite-stable

Anne Hansen Ree, Eirik Høye, Ying Esbensen, Ann-Christin R Beitnes, Anne Negård, Linn Bernklev, Linn Kruse Tetlie, Åsmund A Fretland, Hanne M Hamre, Christian Kersten and 6 more

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03388190 (METIMMOX), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03388190 phase2completednot on this map

METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin

TypeinterventionalSponsorUniversity Hospital, AkershusRan2018 to 2024Enrolled80ConditionsColorectal Cancer MetastaticArmsNivolumab, FLOX
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anne Hansen ReeDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.ORCID 0000-0002-8264-3223
Eirik HøyeInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ying EsbensenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ann-Christin R BeitnesDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway.
Anne NegårdInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Linn BernklevInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Linn Kruse TetlieDepartment of Oncology, Sørlandet Hospital, Kristiansand, Norway.
Åsmund A FretlandThe Intervention Centre and Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.
Hanne M HamreDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.
Christian KerstenDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.
Eva HofsliDepartment of Oncology, St. Olav's Hospital, Trondheim, Norway.
Marianne G GurenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Halfdan SorbyeDepartment of Oncology, Haukeland University Hospital, Bergen, Norway.
Hilde L NilsenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Kjersti FlatmarkInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Sebastian MeltzerDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB). Three of 38 patients assigned to this experimental treatment had metastases from

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsImmune Checkpoint InhibitorsOxaliplatinProto-Oncogene Proteins B-rafAgedAged, 80 and overFemaleHumansMicrosatellite InstabilityMutationRandomized Controlled Trials as TopicTreatment OutcomeBRAF protein, humanImmune Checkpoint InhibitorsOxaliplatinProto-Oncogene Proteins B-rafBRAF mutationcolorectal cancerimmune checkpoint blockademetastasismicrosatellite-stableoxaliplatinT-cell receptor

Identifiers

PMID38952672
PMCPMC11216098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.